Dragos Budinski

430 total citations
9 papers, 356 citations indexed

About

Dragos Budinski is a scholar working on Surgery, Economics and Econometrics and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Dragos Budinski has authored 9 papers receiving a total of 356 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Surgery, 7 papers in Economics and Econometrics and 2 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Dragos Budinski's work include Lipoproteins and Cardiovascular Health (9 papers), Pharmaceutical Economics and Policy (6 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Dragos Budinski is often cited by papers focused on Lipoproteins and Cardiovascular Health (9 papers), Pharmaceutical Economics and Policy (6 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Dragos Budinski collaborates with scholars based in United Kingdom, Japan and Sweden. Dragos Budinski's co-authors include Neil Hounslow, Leiv Ose, Masahiko Gosho, Mats Eriksson, Jakub Gumprecht, N. A. Gratsiansky and Steen Stender and has published in prestigious journals such as Atherosclerosis, Diabetes Obesity and Metabolism and Current Medical Research and Opinion.

In The Last Decade

Dragos Budinski

9 papers receiving 331 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dragos Budinski United Kingdom	9	326	166	122	104	78	9	356
Patrick Ma United States	6	365 1.1×	164 1.0×	91 0.7×	143 1.4×	59 0.8×	8	428
Lorena Garcia Conde Switzerland	10	360 1.1×	98 0.6×	57 0.5×	132 1.3×	81 1.0×	22	571
Evan Stein United States	5	272 0.8×	114 0.7×	82 0.7×	79 0.8×	60 0.8×	7	326
Richard M. Moe United States	5	307 0.9×	181 1.1×	57 0.5×	92 0.9×	111 1.4×	6	447
Marc Ditmarsch United States	11	451 1.4×	245 1.5×	119 1.0×	90 0.9×	122 1.6×	41	554
Geraldine Macdonell United States	7	283 0.9×	185 1.1×	97 0.8×	50 0.5×	52 0.7×	7	344
Michael Lane United States	5	307 0.9×	176 1.1×	83 0.7×	38 0.4×	87 1.1×	6	384
淳佐々木	2	224 0.7×	87 0.5×	49 0.4×	84 0.8×	64 0.8×	2	290
Perry Mar United States	5	355 1.1×	57 0.3×	49 0.4×	203 2.0×	63 0.8×	10	490
Yong‐Joon Lee South Korea	10	357 1.1×	92 0.6×	58 0.5×	118 1.1×	154 2.0×	43	464

Countries citing papers authored by Dragos Budinski

Since Specialization

Citations

This map shows the geographic impact of Dragos Budinski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dragos Budinski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dragos Budinski more than expected).

Fields of papers citing papers by Dragos Budinski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dragos Budinski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dragos Budinski. The network helps show where Dragos Budinski may publish in the future.

Co-authorship network of co-authors of Dragos Budinski

This figure shows the co-authorship network connecting the top 25 collaborators of Dragos Budinski. A scholar is included among the top collaborators of Dragos Budinski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dragos Budinski. Dragos Budinski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Stender, Steen, Dragos Budinski, Masahiko Gosho, & Neil Hounslow. (2012). Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. European Journal of Preventive Cardiology. 20(1). 40–53. 31 indexed citations

Stender, Steen, Dragos Budinski, & Neil Hounslow. (2012). Pitavastatin demonstrates long-term efficacy, safety and tolerability in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. European Journal of Preventive Cardiology. 20(1). 29–39. 16 indexed citations

Eriksson, Mats, Dragos Budinski, & Neil Hounslow. (2011). Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial. Advances in Therapy. 28(9). 811–823. 29 indexed citations

Gumprecht, Jakub, Masahiko Gosho, Dragos Budinski, & Neil Hounslow. (2011). Comparative long‐term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20–40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obesity and Metabolism. 13(11). 1047–1055. 68 indexed citations

Eriksson, Mats, Dragos Budinski, & Neil Hounslow. (2011). Long-term efficacy of pitavastatin versus simvastatin. Advances in Therapy. 28(9). 799–810. 27 indexed citations

Hounslow, Neil, Dragos Budinski, & Mats Eriksson. (2010). MS389 PITAVASTATIN 4 mg SHOWS COMPARABLE LDL-CHOLESTEROL AND SUPERIOR TRIGLYCERIDE REDUCTION TO SIMVASTATIN 40 mg IN HIGH-RISK PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA. Atherosclerosis Supplements. 11(2). 188–188. 8 indexed citations

Ose, Leiv, et al.. (2009). Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis. 210(1). 202–208. 50 indexed citations

Ose, Leiv, et al.. (2009). Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Current Medical Research and Opinion. 25(11). 2755–2764. 68 indexed citations

Budinski, Dragos, et al.. (2009). Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clinical Lipidology. 4(3). 291–302. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact